CSBio CSBio

X
[{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Aditum Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares and Aditum Bio to Advance mGlu5 NAM Clinical Program for Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sosei Heptares"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","amount":"$3,290.0 million","upfrontCash":"$125.0 million","newsHeadline":"Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Sosei Heptares"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$410.0 million","upfrontCash":"$20.0 million","newsHeadline":"Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Asahi Kasei Pharma"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Sosei Group Corporation"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Presents New Findings on Lecanemab's Investigational Subcutaneous Formulation and Modeling Simulation of APOE4 Genotype on Aria-E Incidence at The Alzheimer's Association International Conference (AAIC) 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Eisai"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Sosei Heptares"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            NBI-1117570 is an investigational, oral, muscarinic M1/M4 dual agonist. Muscarinic receptors are fundamental to activating signaling pathways in the brain.

            Lead Product(s): NBI-1117570

            Therapeutic Area: Neurology Product Name: NBI-1117570

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Neurocrine Biosciences

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 11, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Lecanemab (BAN2401) is an investigational humanized monoclonal antibody for Alzheimer's disease selectively binds to neutralize and eliminate soluble, toxic amyloid-beta (Aβ) aggregates (protofibrils) that are thought to contribute to the neurodegenerative process in AD.

            Lead Product(s): Lecanemab

            Therapeutic Area: Neurology Product Name: BAN2401

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: BioArctic AB

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 04, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The trial is a Phase 1, randomized, double-blind, placebo-controlled, first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of a single ascending dose and multiple ascending doses of subcutaneous HTL0022562 in healthy adult subjects.

            Lead Product(s): BHV3100

            Therapeutic Area: Neurology Product Name: HTL0022562

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Biohaven Pharmaceuticals

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 23, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Lilly will be responsible for future global development and regulatory activities for AK1780. AK1780 is an orally bioavailable P2X7 receptor antagonist that recently completed Phase 1 single and multiple ascending dose and clinical pharmacology studies.

            Lead Product(s): AK1780

            Therapeutic Area: Neurology Product Name: AK1780

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Eli Lilly

            Deal Size: $410.0 million Upfront Cash: $20.0 million

            Deal Type: Licensing Agreement January 29, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            AbbVie has notified that it will be returning to Sosei Heptares all assets in development under the program including HTL0018318, all intellectual property licensed by Sosei Heptares to Allergan, and all clinical and preclinical data generated under the partnership.

            Lead Product(s): HTL0018318

            Therapeutic Area: Neurology Product Name: HTL0018318

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Allergan Aesthetics

            Deal Size: $3,290.0 million Upfront Cash: $125.0 million

            Deal Type: Terminated January 05, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Tempero Bio will obtain exclusive global rights to a portfolio of potent, orally available metabotropic glutamate receptor 5 NAM modulators, including HTL0014242, which were precision-designed by Sosei Heptares using its GPCR Structure-Based Drug Design (SBDD) platform.

            Lead Product(s): HTL0014242

            Therapeutic Area: Neurology Product Name: TMP-301

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Aditum Bio

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement November 02, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY